Mingjun Zhang

机构：Northwestern Polytechnical University, Nantong University · ORCID：0009-0007-2493-5141

发表论文 14 篇 · 总被引 70 次 · h-index 3

代表论文

• Toripalimab plus bevacizumab versus sorafenib as first-line treatment for advanced hepatocellular carcinoma (HEPATORCH): a randomised, open-label, phase 3 trial (2025 · ˜The œLancet. Gastroenterology & hepatology · 被引 46)
• Disitamab vedotin (DV) plus toripalimab (Tor) and chemotherapy (C)/trastuzumab (Tra) as first-line (1L) treatment of patients (pts) with HER2-expressing locally advanced or metastatic (la/m) gastric cancer. (2025 · Journal of Clinical Oncology · 被引 9)
• Sacituzumab tirumotecan in participants with advanced or metastatic urothelial carcinoma and disease progression after chemotherapy and immune checkpoint inhibitors (2025 · Annals of Oncology · 被引 5)
• [Research progression in neural invasion model of pancreatic cancer]. (2020 · PubMed · 被引 3)
• Research on the Spatial Differentiation Characteristics and Ecological Protection Paths of "Mountains, Rivers, Forests, Fields, Lakes, and Grasslands" in the Shandong Section of the Yellow River Basin (2024 · Journal of tourism management. · 被引 2)
• IBI354 (anti-HER2 antibody-drug conjugate [ADC]) in patients (pts) with HER2-positive breast cancer (BC) and other solid tumors: Updates from a phase 1 study. (2025 · Journal of Clinical Oncology · 被引 1)